Engineered immune cells take on rare sarcoma in early trial

NCT ID NCT07174427

Recruiting now Disease control Sponsor: Takara Bio Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a personalized cell therapy called TBI-1301 for people with a rare soft-tissue cancer called synovial sarcoma that has spread or come back. The therapy uses a patient's own immune cells, modified to attack cancer cells with a specific marker (NY-ESO-1). About 5 adults will receive the treatment after chemotherapy to prepare their bodies, and researchers will check if tumors shrink.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYNOVIAL SARCOMAS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

synovial sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SYNOVIAL SARCOMAS

Contacts and locations

Show contact details

Locations

Kyusyu University Hospital
RECRUITING

Fukuoka, Japan

Contact Phone: •••-•••-•••• Email: •••••@•••••
Osaka International Cancer Institute
RECRUITING

Osaka, Osaka, 541-8567, Japan

Contact Phone: •••-•••-•••• Email: •••••@•••••